These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 300224)

  • 1. Platelet function and immunologic parameters in von Willebrand's disease following cryoprecipitate and factor VIII concentrate infusion.
    Chediak JR; Telfer MC; Green D
    Am J Med; 1977 Mar; 62(3):369-76. PubMed ID: 300224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Defective ristocetin-induced platelet aggregation in von Willebrand's disease and its correction by factor VIII.
    Weiss HJ; Rogers J; Brand H
    J Clin Invest; 1973 Nov; 52(11):2697-707. PubMed ID: 4201262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dissociation between factor VIII (activity and antigen) and ristocetin-induced platelet aggregation in von Willebrand's disease.
    Barbui T; Dini E
    Acta Haematol; 1975; 53(1):44-8. PubMed ID: 807074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnosis of von Willebrand's disease. A comparative study of diagnostic tests on nine families with von Willebrand's disease and its differential diagnosis from hemophilia and thrombocytopathy.
    Lian EC; Deykin D
    Am J Med; 1976 Mar; 60(3):344-56. PubMed ID: 1083143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acquired von Willebrand syndrome with inhibitors both to factor VIII clotting activity and ristocetin-induced platelet aggregation.
    Stableforth P; Tamagnini GL; Dormandy KM
    Br J Haematol; 1976 Aug; 33(4):565-73. PubMed ID: 1087568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The von Willebrand syndrome.
    Stableforth P; Hughes J; Wilson E; Dormandy KM
    Br J Haematol; 1975 Apr; 29(4):605-16. PubMed ID: 1081404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infusion of human and canine factor VIII in dogs with von Willebrand's disease: studies of the von Willebrand and factor VIII synthesis stimulating factors.
    Bouma BN; Dodds WJ; van Mourik JA; Sixma JJ; Webster WP
    Scand J Haematol; 1976 Oct; 17(4):263-75. PubMed ID: 825957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Failure of AHF concentration to control bleeding in von Willebrand's disease.
    Green D; Potter EV
    Am J Med; 1976 Mar; 60(3):357-60. PubMed ID: 1083144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heat-treated factor VIII/von Willebrand factor concentrate in platelet-type von Willebrand's disease.
    Takahashi H; Tatewaki W; Nagayama R; Hanano M; Tamura M; Yamaguchi T; Takizawa S; Wada K; Shibata A
    Haemostasis; 1987; 17(6):353-60. PubMed ID: 3123334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factor VIII (Willebrand) antigen and ristocetin-Willebrand factor in pigs with von Willebrand's disease.
    Fass DN; Brockway WJ; Owen CA; Bowie EJ
    Thromb Res; 1976 Mar; 8(3):319-27. PubMed ID: 1083569
    [No Abstract]   [Full Text] [Related]  

  • 11. Factor VIII/von Willebrand factor binding to von Willebrand's disease platelets.
    Gralnick HR; Williams SB; Shafer BC; Corash L
    Blood; 1982 Aug; 60(2):328-32. PubMed ID: 6807372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative assay of a plasma factor deficient in von Willebrand's disease that is necessary for platelet aggregation. Relationship to factor VIII procoagulant activity and antigen content.
    Weiss HJ; Hoyer LW; Rickles FR; Varma A; Rogers J
    J Clin Invest; 1973 Nov; 52(11):2708-16. PubMed ID: 4542944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Replacement therapy in platelet-type von Willebrand disease.
    Takahashi H
    Am J Hematol; 1985 Apr; 18(4):351-62. PubMed ID: 3919572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Type IIB von Willebrand's disease: unusual response to cryoprecipitate infusion.
    Weinger RS; Cimo PL; Moake JL; Olson JD; Heller MS
    Ann Intern Med; 1981 Jan; 94(1):47-50. PubMed ID: 6778284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abnormalities of factor VIII and platelet aggregation--use of ristocetin in diagnosing the von Willebrand syndrome.
    Weiss HJ
    Blood; 1975 Mar; 45(3):403-12. PubMed ID: 1078779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelet-bound ristocetin aggregation factor in normal subjects and patients with von Willebrand's disease.
    Green D; Potter EV
    J Lab Clin Med; 1976 Jun; 87(6):976-86. PubMed ID: 778313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of an inhibitor specific to factor VIII: coagulant activity in a patient with platelet-type von Willebrand's disease.
    Castella A; Miller JL; Neuberg RW; Gawryl MS; Hoyer LW
    Am J Clin Pathol; 1983 Nov; 80(5):745-9. PubMed ID: 6416054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. On the characterization of acquired inhibitors to ristocetin induced platelet aggregation found in patients with von Willebrand's disease.
    Egberg N; Blombäck M
    Thromb Res; 1976 Nov; 9(5):527-31. PubMed ID: 1087055
    [No Abstract]   [Full Text] [Related]  

  • 19. A human myeloma-produced monoclonal protein directed against the active subpopulation of von Willebrand factor.
    Bovill EG; Ershler WB; Golden EA; Tindle BH; Edson JR
    Am J Clin Pathol; 1986 Jan; 85(1):115-23. PubMed ID: 3079626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral administration of factor VIII concentrate preparation in von Willebrand's disease.
    Sakuragawa N; Niiya K; Kondo S
    Thromb Res; 1985 Jun; 38(6):681-5. PubMed ID: 3927510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.